276 Reduction of Cardiovascular Disease-Associated Proteins in Blood of Psoriasis Patients After 1-Month Treatment With Tofacitinib or Etanercept

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2016.02.306
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Discontinuation of Etanercept After Successful Treatment in Patients With Juvenile Idiopathic Arthritis

Journal of Rheumatology
RheumatologyAllergyImmunology
2010English

Induction or Exacerbation of Psoriasis in Patients With Crohn's Disease Under Treatment With Anti-TNF Antibodies

Digestion
Gastroenterology
2014English

Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis

Expert Review of Clinical Immunology
AllergyImmunology
2018English

Comparison of Lipid and Lipid-Associated Cardiovascular Risk Marker Changes After Treatment With Tocilizumab or Adalimumab in Patients With Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2015English

The Effect of Etanercept on Traditional Metabolic Risk Factors for Cardiovascular Disease in Patients With Rheumatoid Arthritis

Clinical Rheumatology
MedicineRheumatology
2016English

Pharmacokinetics of Subcutaneously Administered Etanercept in Subjects With Psoriasis

British Journal of Clinical Pharmacology
Pharmacology
2006English

Extent of Cardiovascular Risk Reduction Associated With Treatment of Isolated Systolic Hypertension

Archives of Internal Medicine
2003English

Reduction of Cardiovascular Disease Events by Worksite Hypertension Treatment.

Hypertension
Internal Medicine
1983English

Cardiovascular Disease in Patients With Psoriatic Arthritis: Correlation or Causation?

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy